HC Wainwright Predicts Higher Earnings for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Investment analysts at HC Wainwright increased their Q4 2024 earnings per share (EPS) estimates for shares of TG Therapeutics in a note issued to investors on Monday, November 4th. HC Wainwright analyst E. White now expects that the biopharmaceutical company will earn $0.15 per share for the quarter, up from their prior forecast of $0.11. HC Wainwright has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.13 per share.

Other analysts also recently issued reports about the stock. B. Riley boosted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. TD Cowen assumed coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

TG Therapeutics Stock Performance

TGTX stock opened at $25.86 on Wednesday. The company has a 50-day simple moving average of $23.51 and a 200 day simple moving average of $20.17. The company has a market capitalization of $4.00 billion, a P/E ratio of -258.60 and a beta of 2.19. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. TG Therapeutics has a fifty-two week low of $9.81 and a fifty-two week high of $26.99.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The business had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.73 EPS.

Institutional Trading of TG Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. NBC Securities Inc. grew its position in TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of TG Therapeutics during the second quarter worth $35,000. Blue Trust Inc. raised its position in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares during the period. ORG Wealth Partners LLC purchased a new stake in shares of TG Therapeutics during the third quarter valued at $53,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of TG Therapeutics in the 1st quarter valued at $58,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.